Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Cytosorbents Corporation (CTSO)
USD0.40
+0.01 (+1.70%)
US NASDAQ Healthcare Medical - Devices
Address
305 College Road East 8540
Princeton, NJ, US
Princeton, NJ, US
CEO
Phillip Chan
Website
cytosorbents.com
IPO
2006-08-08
CIK 1175151 ISIN US23283X2062
Description
Cytosorbents Corporation specializes in creating and bringing to market innovative medical devices. Their core expertise lies in a unique blood purification platform, built upon a proprietary adsorbent and porous polymer technology. The company's leading product, CytoSorb, is an extracorporeal filter designed to remove cytokines from the blood. It serves as a complementary treatment in various critical care scenarios, including sepsis, managing complications during and after heart bypass surgery, and improving the viability of donor organs for transplantation. Beyond CytoSorb, Cytosorbents offers a portfolio of specialized devices. These include VetResQ, used to assist in treating critical conditions like sepsis and pancreatitis in animals; CytoSorb-XL, another device targeting sepsis and other severe illnesses; HemoDefend, a platform for purifying blood supplies by removing contaminants that cause transfusion reactions and diseases, as well as anti-A and anti-B antibodies from blood products; K+ontrol, designed for patients with severe, life-threatening hyperkalemia; and ContrastSorb, which extracts intravenous contrast agents following imaging procedures (like CT scans, angiograms, or interventional radiology) to mitigate the risk of contrast-induced kidney damage. The company is also actively developing several new solutions: BetaSorb, aimed at preventing and treating complications from metabolic toxin buildup in chronic kidney disease patients; DrugSorb, which focuses on eliminating harmful chemicals from the bloodstream; and DrugSorb-ATR, an innovative system for removing antithrombotic agents. Originally established as MedaSorb Technologies Corporation in 1997, the company adopted its current name, Cytosorbents Corporation, in May 2010. Its corporate headquarters are situated in Princeton, New Jersey.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD0.40
+0.01 (+1.70%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
156.6K
Beta
1.36
Float Shares
55.01M
Free Float %
87.6%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -7.00% | +0.33% | -3.95% | -7.73% | -8.30% | -8.34% | -32.66% | -82.30% | -92.85% | -85.57% | -99.23% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (13 ratings, all time)
Buy
Price Targets & DCF
Current price
0.40
Ratings Trend (MoM)
50% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 1 | 0 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
-9.22
Distress
Piotroski F-Score
1 / 9
Weak
MOAT Score
3 / 10
No MOAT
Composite Rating
C
Overall Score
2 / 5
Medium
DCF Score
5 / 5
High
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Medical - Devices: +11.2%+4.1% Q1'26: +1.6% (vs Q1'25)
-
EPS growth Medical - Devices: +28.5%+65.8% ★ Q1'26: -229.2% (vs Q1'25)
-
FCF margin FCF growth · Medical - Devices: +30.9%-43.6% Q1'26: -55.1% (vs Q1'25)
-
EBIT margin Medical - Devices: +6.2%-38.4% Q1'26: +0.0% (vs Q1'25)
-
ROIC Medical - Devices: +3.3%-49.5% Q1'26: +0.0% (vs Q1'25)
-
Share dilution Medical - Devices: 0.0%+14.3% Q1'26: +3.3% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Devices: -0.35×-2.28× Q1'26: -1.56× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 2 Rev. Ana. 2 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 2 Rev. Ana. 2 EPS Ana. |
Dec 2029 1 Rev. Ana. 1 EPS Ana. |
Dec 2030 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
4.06M
est: 4.63M (-12.4%)
|
8.21M
est: 9.09M (-9.7%)
|
13.38M
est: 14.92M (-10.3%)
|
20.25M
est: 22.49M (-9.9%)
|
22.77M
est: 24.36M (-6.5%)
|
39.45M
est: 40.80M (-3.3%)
|
40.11M
est: 42.08M (-4.7%)
|
34.69M
est: 33.78M (+2.7%)
|
31.08M
est: 37.16M (-16.3%)
|
35.59M
est: 39.29M (-9.4%)
|
37.06M
est: 37.61M (-1.5%)
|
40.59M
39.73M – 41.45M
+7.9% YoY
|
49.08M
48.02M – 50.05M
+20.9% YoY
|
56.93M
55.70M – 58.05M
+16.0% YoY
|
72.71M
71.14M – 74.15M
+27.7% YoY
|
133.04M
130.17M – 135.67M
+83.0% YoY
|
| EBITDA |
-9.19M
est: -2.75M (-233.6%)
|
-11.86M
est: -5.40M (-119.5%)
|
-8.17M
est: -8.87M (+7.9%)
|
-15.98M
est: -13.38M (-19.5%)
|
-18.74M
est: -14.49M (-29.3%)
|
-9.71M
est: -24.27M (+60.0%)
|
-21.62M
est: -25.03M (+13.6%)
|
-30.00M
est: -20.10M (-49.3%)
|
-27.88M
est: -22.83M (-22.1%)
|
-15.22M
est: -24.14M (+37.0%)
|
-12.74M
est: -23.11M (+44.9%)
|
-24.94M
-25.46M – -24.41M
-7.9% YoY
|
-30.16M
-30.75M – -29.51M
-20.9% YoY
|
-34.97M
-35.67M – -34.22M
-16.0% YoY
|
-44.67M
-45.56M – -43.71M
-27.7% YoY
|
-81.74M
-83.36M – -79.98M
-83.0% YoY
|
| EBIT |
-9.30M
est: -2.92M (-218.5%)
|
-11.85M
est: -5.73M (-106.8%)
|
-8.39M
est: -9.41M (+10.9%)
|
-16.37M
est: -14.18M (-15.4%)
|
-19.32M
est: -15.37M (-25.8%)
|
-10.37M
est: -25.74M (+59.7%)
|
-22.74M
est: -26.54M (+14.3%)
|
-30.89M
est: -21.31M (-44.9%)
|
-29.90M
est: -24.34M (-22.8%)
|
-16.79M
est: -25.73M (+34.8%)
|
-14.24M
est: -24.64M (+42.2%)
|
-26.59M
-27.15M – -26.02M
-7.9% YoY
|
-32.15M
-32.79M – -31.46M
-20.9% YoY
|
-37.29M
-38.03M – -36.48M
-16.0% YoY
|
-47.63M
-48.57M – -46.60M
-27.7% YoY
|
-87.14M
-88.87M – -85.27M
-83.0% YoY
|
| Net Income |
-8.13M
est: -17.78M (+54.3%)
|
-11.94M
est: -21.09M (+43.4%)
|
-8.46M
est: -15.24M (+44.5%)
|
-17.21M
est: -27.65M (+37.8%)
|
-19.27M
est: -33.31M (+42.2%)
|
-7.84M
est: -12.59M (+37.8%)
|
-24.56M
est: -23.90M (-2.8%)
|
-32.81M
est: -48.46M (+32.3%)
|
-29.25M
est: -31.79M (+8.0%)
|
-20.72M
est: -17.40M (-19.0%)
|
-8.20M
est: -9.95M (+17.6%)
|
-10.57M
-10.85M – -10.28M
-6.3% YoY
|
-3.73M
-3.83M – -3.63M
+64.7% YoY
|
1.45M
-2.49M – 4.36M
+138.9% YoY
|
8.71M
8.47M – 8.94M
+500.4% YoY
|
36.09M
35.08M – 37.02M
+314.3% YoY
|
| SGA |
8.01M
est: 2.84M (+181.7%)
|
12.28M
est: 5.58M (+120.1%)
|
15.43M
est: 9.16M (+68.4%)
|
22.88M
est: 13.81M (+65.6%)
|
24.47M
est: 14.96M (+63.5%)
|
31.51M
est: 25.06M (+25.7%)
|
38.48M
est: 25.84M (+48.9%)
|
2.79M
est: 20.75M (-86.5%)
|
38.31M
est: 24.04M (+59.4%)
|
—
est: 25.41M (-100.0%)
|
35.65M
est: 24.33M (+46.5%)
|
26.26M
25.70M – 26.81M
+7.9% YoY
|
31.75M
31.06M – 32.38M
+20.9% YoY
|
36.82M
36.03M – 37.55M
+16.0% YoY
|
47.03M
46.02M – 47.96M
+27.7% YoY
|
86.05M
84.20M – 87.76M
+83.0% YoY
|
| EPS |
-0.33
est: -0.33 (-1.0%)
|
-0.47
est: -0.39 (-21.3%)
|
-0.31
est: -0.28 (-10.7%)
|
-0.56
est: -0.51 (-10.2%)
|
-0.60
est: -0.61 (+2.0%)
|
-0.20
est: -0.23 (+13.5%)
|
-0.57
est: -0.44 (-29.8%)
|
-0.75
est: -0.89 (+15.7%)
|
-0.65
est: -0.51 (-27.1%)
|
-0.38
est: -0.28 (-35.7%)
|
-0.13
est: -0.16 (+18.8%)
|
-0.17
-0.17 – -0.17
-6.3% YoY
|
-0.06
-0.06 – -0.06
+64.7% YoY
|
0.02
-0.04 – 0.07
+125.0% YoY
|
0.14
0.14 – 0.14
+833.3% YoY
|
0.58
0.56 – 0.59
+314.3% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-12 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-11 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-01 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-11.87M
OE per share TTM
-0.19
Owner's Yield
-32.27%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
45.5%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
18
Total invested
3.29M
Insider transactions (90d)
0
Beneficial owners (>5%)
11
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Vega Montiel | 5.05M | 20.92% | 5.05M | — | 5.05M | — | IN | Mexico | 2006-07-24 | ↗ |
| 2 | Chassman, Margie | 4.80M | 19.60% | 4.80M | — | 4.80M | — | IN | USA | 2006-11-20 | ↗ |
| 3 | S | 3.62M | 6.93% | 3.02M | — | 3.62M | — | IA | of Massachusetts | 2024-02-14 | ↗ |
| 4 | Skylands Capital, LLC | 3.25M | 7.30% | 3.16M | — | 3.25M | — | IA | PERSON WITH: | 2024-01-08 | ↗ |
| 5 | 54-1146619 | 3.05M | 6.87% | — | 3.05M | — | 3.05M | IA | State of Virginia, USA | 2024-02-14 | ↗ |
| 6 | James H. Rooney | 3.05M | 6.87% | — | 3.05M | — | 3.05M | IN | UNITED STATES OF AMERICA | 2024-02-14 | ↗ |
| 7 | Peter C. Keefe | 3.05M | 6.87% | — | 3.05M | — | 3.05M | IN | UNITED STATES OF AMERICA | 2024-02-14 | ↗ |
| 8 | The Vanguard Group - 23-1945930 | 2.21M | 5.08% | — | 72.5K | 2.12M | 86.4K | IA | Pennsylvania | 2022-02-09 | ↗ |
| 9 | Kraus | 1.39M | 5.78% | 1.39M | — | 1.39M | — | IN | USA | 2006-07-18 | ↗ |
| 10 | Shipley | 1.25M | 5.05% | 1.25M | — | 1.25M | — | IN | USA | 2006-07-21 | ↗ |
| 11 | (1) BlackRock, Inc. | 745.0K | 1.70% | 743.8K | — | 745.0K | — | HC | Delaware | 2022-07-08 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
18
-33 vs prev Q
New positions
7
Closed positions
40
Increased
9
Reduced
3
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | EP WEALTH ADVISORS, LLC | 28.0K +28.0K (+100.0%) | 17.90M +17.9M (+100.0%) | 0.04% +0.045 pp | 0.00% +0.000 pp | USD0.64 +0.0% | 1 qtrs NEW |
| 2 | AVENIR CORP | 5.23M +147.3K (+2.9%) | 3.34M -1.4M (-29.6%) | 8.33% +0.216 pp | 0.36% -0.132 pp | USD3.21 -80.1% | 31 qtrs — |
| 3 | VANGUARD GROUP INC | 2.20M +— (+0.0%) | 1.41M -650.3K (-31.6%) | 3.51% -0.008 pp | 0.00% +0.000 pp | USD6.91 -90.7% | 44 qtrs — |
| 4 | SKYLANDS CAPITAL, LLC | 1.85M -272.8K (-12.8%) | 1.19M -801.7K (-40.3%) | 2.96% -0.443 pp | 0.16% -0.114 pp | USD4.61 -86.1% | 42 qtrs — |
| 5 | NEUBERGER BERMAN GROUP LLC | 1.63M +27.6K (+1.7%) | 1.04M -451.3K (-30.3%) | 2.59% +0.038 pp | 0.00% 0.000 pp | USD4.90 -86.9% | 22 qtrs — |
| 6 | CM MANAGEMENT, LLC | 1.48M +188.4K (+14.6%) | 943.8K -259.5K (-21.6%) | 2.35% +0.295 pp | 0.80% -0.208 pp | USD1.71 -62.6% | 20 qtrs — |
| 7 | BLACKROCK, INC. | 770.6K +5.7K (+0.8%) | 492.5K -221.9K (-31.1%) | 1.23% +0.006 pp | 0.00% +0.000 pp | USD1.45 -55.9% | 6 qtrs — |
| 8 | SARGENT INVESTMENT GROUP, LLC | 612.0K -126.7K (-17.2%) | 391.2K -298.8K (-43.3%) | 0.98% -0.205 pp | 0.05% -0.049 pp | USD4.75 -86.5% | 29 qtrs — |
| 9 | GEODE CAPITAL MANAGEMENT, LLC | 603.8K +2.3K (+0.4%) | 386.0K -175.9K (-31.3%) | 0.96% +0.002 pp | 0.00% +0.000 pp | USD6.01 -89.4% | 44 qtrs — |
| 10 | PATHSTONE HOLDINGS, LLC | 500.0K +500.0K (+100.0%) | 319.6K +319.6K (+100.0%) | 0.80% +0.797 pp | 0.00% +0.001 pp | USD0.64 +0.0% | 1 qtrs NEW |
| 11 | CIBC PRIVATE WEALTH GROUP, LLC | 172.6K +— (+0.0%) | 110.4K -50.9K (-31.6%) | 0.28% -0.001 pp | 0.00% 0.000 pp | USD1.66 -61.4% | 10 qtrs — |
| 12 | STATE STREET CORP | 159.3K +— (+0.0%) | 101.8K -47.0K (-31.6%) | 0.25% -0.001 pp | 0.00% +0.000 pp | USD8.78 -92.7% | 44 qtrs — |
| 13 | CITADEL ADVISORS LLC | 149.3K +83.6K (+127.2%) | 95.4K +34.1K (+55.5%) | 0.24% +0.133 pp | 0.00% +0.000 pp | USD0.77 -16.9% | 6 qtrs — |
| 14 | GSA CAPITAL PARTNERS LLP | 148.4K +36.2K (+32.2%) | 95.0K -10.0K (-9.5%) | 0.24% +0.057 pp | 0.01% -0.001 pp | USD0.86 -25.6% | 4 qtrs — |
| 15 | ADVISOR GROUP HOLDINGS, INC. | 130.4K +— (+0.0%) | 83.4K -39.0K (-31.8%) | 0.21% -0.001 pp | 0.00% +0.000 pp | USD3.25 -80.3% | 24 qtrs — |
| 16 | MORGAN STANLEY | 116.5K +9.2K (+8.6%) | 74.5K -25.7K (-25.7%) | 0.19% +0.014 pp | 0.00% +0.000 pp | USD3.65 -82.5% | 44 qtrs — |
| 17 | UBS GROUP AG | 115.3K +69.0 (+0.1%) | 73.7K -33.9K (-31.5%) | 0.18% 0.000 pp | 0.00% +0.000 pp | USD0.93 -31.2% | 33 qtrs — |
| 18 | RAYMOND JAMES FINANCIAL INC | 108.7K -19.0 (0.0%) | 69.5K -32.1K (-31.6%) | 0.17% 0.000 pp | 0.00% +0.000 pp | USD0.91 -29.7% | 5 qtrs — |
| 19 | NWF ADVISORY SERVICES INC. | 104.1K +— (+0.0%) | 66.6K -30.7K (-31.6%) | 0.17% 0.000 pp | 0.01% -0.003 pp | USD1.00 -36.0% | 12 qtrs — |
| 20 | RENAISSANCE TECHNOLOGIES LLC | 100.1K -34.7K (-25.7%) | 64.0K -61.9K (-49.2%) | 0.16% -0.056 pp | 0.00% 0.000 pp | USD1.28 -50.0% | 16 qtrs — |
| 21 | NORTHERN TRUST CORP | 92.5K +980.0 (+1.1%) | 59.2K -26.4K (-30.8%) | 0.15% +0.001 pp | 0.00% +0.000 pp | USD8.17 -92.2% | 44 qtrs — |
| 22 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 83.4K -14.9K (-15.1%) | 53.3K -38.5K (-41.9%) | 0.13% -0.024 pp | 0.00% +0.000 pp | USD1.28 -50.0% | 3 qtrs — |
| 23 | KEY CLIENT FIDUCIARY ADVISORS, LLC | 78.5K +— (+0.0%) | 50.2K -23.1K (-31.6%) | 0.13% 0.000 pp | 0.02% -0.007 pp | USD1.15 -44.3% | 15 qtrs — |
| 24 | WAVERLY ADVISORS, LLC | 55.6K +— (+0.0%) | 35.5K -16.4K (-31.6%) | 0.09% 0.000 pp | 0.00% 0.000 pp | USD0.93 -31.2% | 2 qtrs — |
| 25 | STIFEL FINANCIAL CORP | 48.0K +— (+0.0%) | 30.7K -14.2K (-31.6%) | 0.08% 0.000 pp | 0.00% +0.000 pp | USD1.10 -41.8% | 9 qtrs — |
| 26 | BANK OF AMERICA CORP /DE/ | 38.7K +3.0 (+0.0%) | 24.7K -11.4K (-31.6%) | 0.06% 0.000 pp | 0.00% +0.000 pp | USD3.70 -82.7% | 35 qtrs — |
| 27 | GOLDMAN SACHS GROUP INC | 36.0K -24.6K (-40.6%) | 23.0K -33.6K (-59.4%) | 0.06% -0.039 pp | 0.00% +0.000 pp | USD0.96 -33.3% | 5 qtrs — |
| 28 | XTX TOPCO LTD | 29.7K +29.7K (+100.0%) | 19.0K +19.0K (+100.0%) | 0.05% +0.047 pp | 0.00% +0.001 pp | USD0.64 +0.0% | 1 qtrs NEW |
| 29 | ATOMI FINANCIAL GROUP, INC. | 27.4K +— (+0.0%) | 17.5K -8.1K (-31.6%) | 0.04% 0.000 pp | 0.00% 0.000 pp | USD1.50 -57.3% | 6 qtrs — |
| 30 | KESTRA ADVISORY SERVICES, LLC | 25.7K -38.8K (-60.2%) | 16.4K -43.8K (-72.7%) | 0.04% -0.062 pp | 0.00% 0.000 pp | USD1.04 -38.5% | 6 qtrs — |
| 31 | LPL FINANCIAL LLC | 23.1K +8.2K (+54.7%) | 14.7K +820.0 (+5.9%) | 0.04% +0.013 pp | 0.00% +0.000 pp | USD0.83 -22.9% | 2 qtrs — |
| 32 | CREATIVE PLANNING | 21.3K -160.0 (-0.7%) | 13.6K -6.4K (-32.1%) | 0.03% 0.000 pp | 0.00% +0.000 pp | USD9.58 -93.3% | 31 qtrs — |
| 33 | SEELAUS ASSET MANAGEMENT LLC | 17.3K +— (+0.0%) | 11.1K -5.1K (-31.6%) | 0.03% 0.000 pp | 0.01% -0.004 pp | USD7.93 -91.9% | 22 qtrs — |
| 34 | MERIT FINANCIAL GROUP, LLC | 15.3K +— (+0.0%) | 9.8K -4.5K (-31.6%) | 0.02% 0.000 pp | 0.00% 0.000 pp | USD1.49 -57.0% | 6 qtrs — |
| 35 | FIRST NATIONAL BANK OF OMAHA | 15.2K +15.2K (+100.0%) | 9.8K +9.8K (+100.0%) | 0.02% +0.024 pp | 0.00% +0.000 pp | USD0.64 +0.0% | 1 qtrs NEW |
| 36 | TEXAS CAPITAL BANK WEALTH MANAGEMENT SERVICES INC | 11.0K +11.0K (+100.0%) | 7.0K +7.0K (+100.0%) | 0.02% +0.018 pp | 0.00% +0.000 pp | USD0.64 +0.0% | 1 qtrs NEW |
| 37 | VIRTU FINANCIAL LLC | 10.8K +10.8K (+100.0%) | 7.0K +7.0K (+100.0%) | 0.02% +0.017 pp | 0.00% +0.000 pp | USD0.64 +0.0% | 1 qtrs NEW |
| 38 | MILLENNIUM MANAGEMENT LLC | 10.2K +10.2K (+100.0%) | 6.5K +6.5K (+100.0%) | 0.02% +0.016 pp | 0.00% +0.000 pp | USD0.64 +0.0% | 1 qtrs NEW |
| 39 | COMERICA BANK | 4.4K +819.0 (+23.0%) | 2.8K -526.0 (-15.8%) | 0.01% +0.001 pp | 0.00% +0.000 pp | USD0.82 -22.0% | 10 qtrs — |
| 40 | ROCKEFELLER CAPITAL MANAGEMENT L.P. | 2.6K +1.6K (+156.6%) | 1.6K +707.0 (+75.7%) | 0.00% +0.003 pp | 0.00% +0.000 pp | USD0.75 -14.7% | 2 qtrs — |
| 41 | GLOBAL RETIREMENT PARTNERS, LLC | 2.3K +2.3K (+100.0%) | 1.4K +1.4K (+100.0%) | 0.00% +0.004 pp | 0.00% +0.000 pp | USD0.64 +0.0% | 1 qtrs NEW |
| 42 | TOWER RESEARCH CAPITAL LLC (TRC) | 2.2K -3.4K (-61.3%) | 1.4K -3.9K (-73.5%) | 0.00% -0.006 pp | 0.00% 0.000 pp | USD0.94 -31.9% | 11 qtrs — |
| 43 | WELLS FARGO & COMPANY/MN | 730.00 +— (+0.0%) | 467.00 -215.0 (-31.5%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD2.20 -70.9% | 34 qtrs — |
| 44 | FMR LLC | 384.00 +384.0 (+100.0%) | 245.00 +245.0 (+100.0%) | 0.00% +0.001 pp | 0.00% +0.000 pp | USD0.64 +0.0% | 1 qtrs NEW |
| 45 | JPMORGAN CHASE & CO | 372.00 +— (+0.0%) | 238.00 -109.0 (-31.4%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD3.28 -80.5% | 41 qtrs — |
| 46 | YOUR ADVOCATES LTD., LLP | 250.00 +— (+0.0%) | 160.00 -73.0 (-31.3%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD1.55 -58.7% | 20 qtrs — |
| 47 | MAI CAPITAL MANAGEMENT | 233.00 +— (+0.0%) | 149.00 -69.0 (-31.7%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD0.96 -33.3% | 5 qtrs — |
| 48 | JONES FINANCIAL COMPANIES LLLP | 93.00 -500.0 (-84.3%) | 59.00 -494.0 (-89.3%) | 0.00% -0.001 pp | 0.00% +0.000 pp | USD0.92 -30.4% | 2 qtrs — |
| 49 | PNC FINANCIAL SERVICES GROUP, INC. | 31.00 +— (+0.0%) | 20.00 -9.0 (-31.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD1.06 -39.6% | 9 qtrs — |
| 50 | BNP PARIBAS ARBITRAGE, SNC | 20.00 +— (+0.0%) | 13.00 -6.0 (-31.6%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD2.15 -70.2% | 31 qtrs — |
| 51 | CHICAGO PARTNERS INVESTMENT GROUP LLC | — -14.2K (-100.0%) | — -11.9K (-100.0%) | 0.00% -0.023 pp | 0.00% 0.000 pp | USD— | 16 qtrs SOLD |
| 52 | SBI SECURITIES CO., LTD. | — -1.0 (-100.0%) | — -1.0 (-100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD— | 5 qtrs SOLD |
| 53 | TWO SIGMA SECURITIES, LLC | — -15.7K (-100.0%) | — -14.7K (-100.0%) | 0.00% -0.025 pp | 0.00% -0.002 pp | USD— | 6 qtrs SOLD |
| 54 | ROYAL BANK OF CANADA | — -1.1K (-100.0%) | — -1.0K (-100.0%) | 0.00% -0.002 pp | 0.00% +0.000 pp | USD— | 3 qtrs SOLD |
| 55 | SEI INVESTMENTS CO | — -17.7K (-100.0%) | — -16.6K (-100.0%) | 0.00% -0.028 pp | 0.00% +0.000 pp | USD— | 15 qtrs SOLD |
| 56 | CENTIVA CAPITAL, LP | — -10.7K (-100.0%) | — -10.0K (-100.0%) | 0.00% -0.017 pp | 0.00% 0.000 pp | USD— | 2 qtrs SOLD |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 11 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Vanguard Extended Market ETF VXF | 0.00% | 275.6K | 0.05% |
| 2 | Vanguard U.S. Total Market Shares Index ETF VTS.AX | 0.00% | 1.3K | 0.03% |
| 3 | Vanguard U.S. Total Market Index ETF VUN.TO | 0.00% | 3.6K | 0.17% |
| 4 | Vanguard U.S. Total Market Index ETF (CAD-hedged) VUS.TO | 0.00% | 268.86 | 0.17% |
| 5 | Vanguard Total Stock Market ETF VTI | 0.00% | 622.2K | 0.03% |
| 6 | Vanguard All-Equity ETF Portfolio VEQT.TO | 0.00% | 1.4K | 0.22% |
| 7 | Vanguard Growth ETF Portfolio VGRO.TO | 0.00% | 742.02 | 0.22% |
| 8 | Vanguard Balanced ETF Portfolio VBAL.TO | 0.00% | 299.95 | 0.22% |
| 9 | Vanguard Conservative ETF Portfolio VCNS.TO | 0.00% | 33.03 | 0.22% |
| 10 | Vanguard Conservative Income ETF Portfolio VCIP.TO | 0.00% | 4.64 | 0.22% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Buys
1
Sells
0
Shares acquired
100.0K
Shares disposed
—
Cash buys
—
Cash sales
—
Net activity
+100,000
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-11-18 | Chan Phillip P. | Director / Officer | A-Award | A | Common Stock | 100,000 | 0.64 | 64.0K | 1,482,963 | D | ↗ |
| 2025-08-08 | Sobel Alan D. | Director | A-Award | A | Stock Option (Right to Buy) | 22,000 | 1.00 | 22.0K | 22,000 | D | ↗ |
| 2025-08-08 | MARIANI PETER J | Officer | A-Award | A | Stock Option (Right to Buy) | 90,000 | 1.00 | 90.0K | 90,000 | D | ↗ |
| 2025-08-08 | Kim Jiny | Director | A-Award | A | Stock Option (Right to Buy) | 22,000 | 1.00 | 22.0K | 22,000 | D | ↗ |
| 2025-08-08 | Jones Edward Raymond | Director | A-Award | A | Stock Option (Right to Buy) | 22,000 | 1.00 | 22.0K | 22,000 | D | ↗ |
| 2025-08-08 | Deliargyris Efthymios | Officer | A-Award | A | Stock Option (Right to Buy) | 95,000 | 1.00 | 95.0K | 95,000 | D | ↗ |
| 2025-08-08 | Chan Phillip P. | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 136,400 | 1.00 | 136.4K | 136,400 | D | ↗ |
| 2025-08-08 | Capponi Vincent | Officer | A-Award | A | Stock Option (Right to Buy) | 111,100 | 1.00 | 111.1K | 111,100 | D | ↗ |
| 2025-08-08 | BATOR MICHAEL G. | Director | A-Award | A | Stock Option (Right to Buy) | 44,000 | 1.00 | 44.0K | 44,000 | D | ↗ |
| 2025-02-24 | Sobel Alan D. | Director | O-OutOfTheMoney | D | Series A Right Warrants (right to buy) | 21,950 | 1.13 | 24.8K | 0 | D | ↗ |
| 2025-02-24 | MARIANI PETER J | Officer | O-OutOfTheMoney | D | Series A Right Warrants (right to buy) | 32,625 | 1.13 | 36.9K | 0 | D | ↗ |
| 2025-02-24 | Chan Phillip P. | Director / Officer | O-OutOfTheMoney | D | Series A Right Warrants (right to buy) | 34,168 | 1.13 | 38.6K | 0 | D | ↗ |
| 2025-02-24 | Capponi Vincent | Officer | O-OutOfTheMoney | D | Series A Right Warrants (right to buy) | 12,000 | 1.13 | 13.6K | 0 | D | ↗ |
| 2025-02-24 | BATOR MICHAEL G. | Director | O-OutOfTheMoney | D | Series A Right Warrants (right to buy) | 15,879 | 1.13 | 17.9K | 0 | D | ↗ |
| 2025-01-17 | Sobel Alan D. | Director | X-InTheMoney | A | Common Stock | 21,950 | 1.00 | 22.0K | 123,807 | D | ↗ |
| 2025-01-17 | MARIANI PETER J | Officer | X-InTheMoney | D | Subscription Rights (right to buy) | 32,625 | 1.00 | 32.6K | 0 | D | ↗ |
| 2025-01-17 | Deliargyris Efthymios | Officer | X-InTheMoney | D | Subscription Rights (right to buy) | 16,233 | 1.00 | 16.2K | 0 | D | ↗ |
| 2025-01-17 | Chan Phillip P. | Director / Officer | X-InTheMoney | D | Subscription Rights (right to buy) | 90,832 | 1.00 | 90.8K | 0 | D | ↗ |
| 2025-01-17 | Capponi Vincent | Officer | X-InTheMoney | D | Subscription Rights (right to buy) | 31,760 | 1.00 | 31.8K | 0 | D | ↗ |
| 2025-01-17 | BATOR MICHAEL G. | Director | J-Other | A | Series A Right Warrants | 15,879 | 0.00 | — | 15,879 | D | ↗ |
| 2024-12-13 | MARIANI PETER J | Officer | P-Purchase | A | Common Stock | 20,000 | 0.96 | 19.3K | 401,363 | D | ↗ |
| 2024-12-12 | MARIANI PETER J | Officer | P-Purchase | A | Common Stock | 20,000 | 0.89 | 17.9K | 381,363 | D | ↗ |
| 2024-12-11 | MARIANI PETER J | Officer | P-Purchase | A | Common Stock | 11,363 | 0.89 | 10.1K | 361,363 | D | ↗ |
| 2024-10-04 | Deliargyris Efthymios | Officer | A-Award | A | Stock Option (Right to Buy) | 50,000 | 1.19 | 59.5K | 50,000 | D | ↗ |
| 2024-10-04 | Capponi Vincent | Officer | A-Award | A | Stock Option (Right to Buy) | 50,000 | 1.19 | 59.5K | 50,000 | D | ↗ |
| 2024-08-14 | MARIANI PETER J | Officer | A-Award | A | Common Stock | 175,000 | 0.00 | — | 350,000 | — | ↗ |
| 2024-04-02 | Sobel Alan D. | Director | A-Award | A | Stock Option (Right to Buy) | 22,000 | 0.96 | 21.0K | 22,000 | — | ↗ |
| 2024-04-02 | Kim Jiny | Director | A-Award | A | Stock Option (Right to Buy) | 22,000 | 0.96 | 21.0K | 22,000 | — | ↗ |
| 2024-04-02 | Jones Edward Raymond | Director | A-Award | A | Stock Option (Right to Buy) | 22,000 | 0.96 | 21.0K | 22,000 | — | ↗ |
| 2024-04-02 | Deliargyris Efthymios | Officer | A-Award | A | Stock Option (Right to Buy) | 86,000 | 0.96 | 82.1K | 86,000 | — | ↗ |
| 2024-04-02 | Chan Phillip P. | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 124,000 | 0.96 | 118.4K | 124,000 | — | ↗ |
| 2024-04-02 | Capponi Vincent | Officer | A-Award | A | Common Stock | 81,000 | 0.00 | — | 665,134 | — | ↗ |
| 2024-04-02 | BLOCH KATHLEEN P. | Officer | A-Award | A | Common Stock | 65,000 | 0.00 | — | 532,941 | — | ↗ |
| 2024-04-02 | BATOR MICHAEL G. | Director | A-Award | A | Stock Option (Right to Buy) | 44,000 | 0.96 | 42.0K | 44,000 | — | ↗ |
| 2024-03-29 | Deliargyris Efthymios | Officer | A-Award | A | Stock Option (Right to Buy) | 47,088 | 0.95 | 44.7K | 47,088 | — | ↗ |
| 2024-03-29 | Chan Phillip P. | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 129,998 | 0.95 | 123.5K | 129,998 | — | ↗ |
| 2024-03-29 | Capponi Vincent | Officer | A-Award | A | Stock Option (Right to Buy) | 48,923 | 0.95 | 46.5K | 48,923 | — | ↗ |
| 2024-03-29 | BLOCH KATHLEEN P. | Officer | A-Award | A | Stock Option (Right to Buy) | 49,038 | 0.95 | 46.6K | 49,038 | — | ↗ |
| 2023-12-13 | Sobel Alan D. | Director | P-Purchase | A | Common Stock | 22,557 | 1.33 | 30.0K | 101,857 | — | ↗ |
| 2023-12-13 | Kim Jiny | Director | P-Purchase | A | Common Stock Warrant (Right to Buy) | 2,631 | 2.00 | 5.3K | 2,631 | — | ↗ |
| 2023-12-13 | Jones Edward Raymond | Director | P-Purchase | A | Common Stock | 7,519 | 1.33 | 10.0K | 88,834 | — | ↗ |
| 2023-12-13 | Deliargyris Efthymios | Officer | P-Purchase | A | Common Stock | 22,557 | 1.33 | 30.0K | 348,433 | — | ↗ |
| 2023-12-13 | Chan Phillip P. | Director / Officer | P-Purchase | A | Common Stock | 75,188 | 1.33 | 100.0K | 1,068,704 | — | ↗ |
| 2023-12-13 | Capponi Vincent | Officer | P-Purchase | A | Common Stock Warrant (Right to Buy) | 6,578 | 2.00 | 13.2K | 6,578 | — | ↗ |
| 2023-12-13 | BLOCH KATHLEEN P. | Officer | P-Purchase | A | Common Stock | 37,594 | 1.33 | 50.0K | 467,941 | — | ↗ |
| 2023-12-13 | BATOR MICHAEL G. | Director | P-Purchase | A | Common Stock Warrant (Right to Buy) | 13,157 | 2.00 | 26.3K | 13,157 | — | ↗ |
| 2023-09-18 | BLOCH KATHLEEN P. | Officer | A-Award | A | Common Stock | 45,000 | 0.00 | — | 442,347 | — | ↗ |
| 2023-08-07 | D'Amico Alex | Officer | — | D | Common Stock | 0 | 0.00 | — | 210,000 | — | ↗ |
| 2023-08-07 | BATOR MICHAEL G. | Director | P-Purchase | A | Common Stock | 1,000 | 3.15 | 3.2K | 87,800 | — | ↗ |
| 2023-08-04 | BATOR MICHAEL G. | Director | P-Purchase | A | Common Stock | 1,000 | 3.23 | 3.2K | 85,800 | — | ↗ |
| 2023-07-07 | Sobel Alan D. | Director | A-Award | A | Stock Option (right to buy) | 20,000 | 3.53 | 70.6K | 20,000 | — | ↗ |
| 2023-07-07 | Kim Jiny | Director | A-Award | A | Stock Option (right to buy) | 20,000 | 3.53 | 70.6K | 20,000 | — | ↗ |
| 2023-07-07 | Jones Edward Raymond | Director | A-Award | A | Stock Option (right to buy) | 20,000 | 3.53 | 70.6K | 20,000 | — | ↗ |
| 2023-07-07 | Deliargyris Efthymios | Officer | A-Award | A | Common Stock | 55,000 | 0.00 | — | 331,648 | — | ↗ |
| 2023-07-07 | Chan Phillip P. | Director / Officer | A-Award | D | Stock Option (right to buy) | 48,000 | 3.53 | 169.4K | 48,000 | — | ↗ |
| 2023-07-07 | Capponi Vincent | Officer | A-Award | A | Stock Option (right to buy) | 91,000 | 3.53 | 321.2K | 91,000 | — | ↗ |
| 2023-07-07 | BLOCH KATHLEEN P. | Officer | A-Award | A | Stock Option (Right to Buy) | 20,000 | 3.53 | 70.6K | 20,000 | — | ↗ |
| 2023-07-07 | BATOR MICHAEL G. | Director | A-Award | A | Stock Option (right to buy) | 40,000 | 3.53 | 141.2K | 40,000 | — | ↗ |
| 2023-05-25 | BLOCH KATHLEEN P. | Officer | P-Purchase | A | Common Stock | 1,100 | 2.85 | 3.1K | 47,000 | — | ↗ |
| 2023-05-10 | BLOCH KATHLEEN P. | Officer | P-Purchase | A | Common Stock | 5,000 | 3.06 | 15.3K | 38,700 | — | ↗ |
| 2023-04-04 | Capponi Vincent | Officer | M-Exempt | A | Common Stock | 10,000 | 2.88 | 28.8K | 511,989 | — | ↗ |
| 2023-04-03 | Chan Phillip P. | Officer | M-Exempt | A | Common Stock | 30,500 | 2.88 | 87.7K | 927,779 | — | ↗ |
| 2023-02-27 | Sobel Alan D. | Director | G-Gift | A | Common Stock | 2,000 | 0.00 | — | 81,300 | — | ↗ |
| 2023-02-06 | Kraus Al | Director | M-Exempt | A | Common Stock | 12,000 | 2.65 | 31.8K | 142,046 | — | ↗ |
| 2022-12-08 | Chan Phillip P. | Officer | P-Purchase | A | Common Stock | 5,859 | 1.26 | 7.4K | 897,279 | — | ↗ |
| 2022-12-07 | Chan Phillip P. | Officer | P-Purchase | A | Common Stock | 9,850 | 1.26 | 12.4K | 891,420 | — | ↗ |
| 2022-12-06 | Chan Phillip P. | Officer | P-Purchase | A | Common Stock | 14,291 | 1.26 | 18.1K | 881,570 | — | ↗ |
| 2022-09-08 | Chan Phillip P. | Director / Officer | P-Purchase | A | Common Stock | 35,000 | 1.70 | 59.5K | 867,279 | — | ↗ |
| 2022-08-25 | Kim Jiny | Director | P-Purchase | A | Common Stock | 1,000 | 1.91 | 1.9K | 70,300 | — | ↗ |
| 2022-08-10 | Sobel Alan D. | Director | A-Award | A | Stock Option (right to buy) | 18,975 | 1.95 | 37.0K | 18,975 | — | ↗ |
| 2022-08-10 | Kraus Al | Director | A-Award | A | Stock Option (right to buy) | 37,950 | 0.00 | — | 37,950 | — | ↗ |
| 2022-08-10 | Kim Jiny | Director | A-Award | A | Stock Option (right to buy) | 18,975 | 0.00 | — | 18,975 | — | ↗ |
| 2022-08-10 | Jones Edward Raymond | Director | A-Award | A | Stock Option (right to buy) | 18,975 | 0.00 | — | 18,975 | — | ↗ |
| 2022-08-10 | Deliargyris Efthymios | Officer | A-Award | A | Stock Option (right to buy) | 300,000 | 0.00 | — | 300,000 | — | ↗ |
| 2022-08-10 | Chan Phillip P. | Director / Officer | A-Award | A | Stock Option (right to buy) | 106,000 | 1.95 | 206.7K | 106,000 | — | ↗ |
| 2022-08-10 | Capponi Vincent | Officer | A-Award | A | Stock Option (right to buy) | 250,000 | 1.95 | 487.5K | 250,000 | — | ↗ |
| 2022-08-10 | BLOCH KATHLEEN P. | Officer | A-Award | A | Stock Option (right to buy) | 75,000 | 1.95 | 146.3K | 75,000 | — | ↗ |
| 2022-08-10 | BATOR MICHAEL G. | Director | A-Award | A | Stock Option (right to buy) | 18,975 | 1.95 | 37.0K | 18,975 | — | ↗ |
| 2022-06-21 | Capponi Vincent | Officer | P-Purchase | A | Common Stock | 2,000 | 1.80 | 3.6K | 443,545 | — | ↗ |
| 2022-06-16 | Chan Phillip P. | Officer | P-Purchase | A | Common Stock | 2,221 | 1.85 | 4.1K | 768,351 | — | ↗ |
| 2022-06-16 | Capponi Vincent | Officer | P-Purchase | A | Common Stock | 3,000 | 2.00 | 6.0K | 441,545 | — | ↗ |
| 2022-06-09 | Chan Phillip P. | Officer | P-Purchase | A | Common Stock | 16,000 | 2.17 | 34.8K | 766,130 | — | ↗ |
| 2022-06-06 | BLOCH KATHLEEN P. | Officer | P-Purchase | A | Common Stock | 8,700 | 1.90 | 16.5K | 33,700 | — | ↗ |
| 2022-05-23 | Capponi Vincent | Officer | P-Purchase | A | Common Stock | 3,127 | 2.03 | 6.3K | 438,545 | — | ↗ |
| 2022-05-18 | BATOR MICHAEL G. | Director | P-Purchase | A | Common Stock | 1,000 | 2.21 | 2.2K | 84,800 | — | ↗ |
| 2022-05-16 | Jones Edward Raymond | Director | P-Purchase | A | Common Stock | 1,676 | 2.24 | 3.7K | 81,315 | — | ↗ |
| 2022-05-11 | Sobel Alan D. | Director | P-Purchase | A | Common Stock | 1,200 | 2.00 | 2.4K | 70,500 | — | ↗ |
| 2022-05-06 | Kraus Al | Director | P-Purchase | A | Common Stock | 5,000 | 1.96 | 9.8K | 130,046 | — | ↗ |
| 2022-04-05 | Kim Jiny | Director | A-Award | A | Common Stock | 69,300 | 0.00 | — | 69,300 | — | ↗ |
| 2022-04-01 | Kim Jiny | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2022-02-14 | Sobel Alan D. | Director | G-Gift | A | Common Stock | 2,000 | 0.00 | — | 2,000 | — | ↗ |
| 2021-12-30 | Chan Phillip P. | Officer | P-Purchase | A | Common Stock | 5,462 | 4.05 | 22.1K | 768,443 | — | ↗ |
| 2021-12-29 | Chan Phillip P. | Officer | P-Purchase | A | Common Stock | 9,438 | 4.05 | 38.2K | 762,981 | — | ↗ |
| 2021-12-10 | Chan Phillip P. | Officer | P-Purchase | A | Common Stock | 5,000 | 5.25 | 26.3K | 753,443 | — | ↗ |
| 2021-12-09 | Jones Edward Raymond | Director | M-Exempt | A | Common Stock | 4,000 | 4.13 | 16.5K | 82,800 | — | ↗ |
| 2021-11-23 | BLOCH KATHLEEN P. | Officer | P-Purchase | A | Common Stock | 4,000 | 4.98 | 19.9K | 25,000 | — | ↗ |
| 2021-08-31 | Kraus Al | Director | S-Sale | D | Common Stock | 4,000 | 9.40 | 37.6K | 125,046 | — | ↗ |
| 2021-04-12 | Sobel Alan D. | Director | A-Award | A | Stock Option (right to buy) | 17,250 | 8.99 | 155.1K | 17,250 | — | ↗ |
| 2021-04-12 | Kraus Al | Director | A-Award | A | Stock Option (right to buy) | 34,500 | 8.99 | 310.2K | 34,500 | — | ↗ |
| 2021-04-12 | Jones Edward Raymond | Director | A-Award | A | Stock Option (right to buy) | 17,250 | 8.99 | 155.1K | 17,250 | — | ↗ |
| 2021-04-12 | Deliargyris Efthymios | Officer | A-Award | A | Stock Option (right to buy) | 63,250 | 8.99 | 568.6K | 63,250 | — | ↗ |
| 2021-04-12 | Chan Phillip P. | Officer | A-Award | A | Stock Option (right to buy) | 96,000 | 8.99 | 863.0K | 96,000 | — | ↗ |
| 2021-04-12 | Capponi Vincent | Officer | A-Award | A | Common Stock | 62,215 | 8.99 | 559.3K | 467,756 | — | ↗ |
| 2021-04-12 | BLOCH KATHLEEN P. | Officer | A-Award | A | Common Stock | 49,450 | 8.99 | 444.6K | 375,372 | — | ↗ |
| 2021-04-12 | BATOR MICHAEL G. | Director | A-Award | A | Stock Option (right to buy) | 17,250 | 8.99 | 155.1K | 17,250 | — | ↗ |
| 2020-12-31 | BLOCH KATHLEEN P. | Officer | M-Exempt | A | Common Stock | 7,857 | 5.60 | 44.0K | 333,013 | — | ↗ |
| 2020-11-10 | Kraus Al | Director | M-Exempt | A | Common Stock | 8,000 | 3.45 | 27.6K | 133,046 | — | ↗ |
| 2020-08-18 | Jones Edward Raymond | Director | M-Exempt | D | Stock Option (right to buy) | 4,000 | 3.35 | 13.4K | 0 | — | ↗ |
| 2020-07-31 | BLOCH KATHLEEN P. | Officer | M-Exempt | A | Stock Option (right to buy) | 10,000 | 5.60 | 56.0K | 55,650 | — | ↗ |
| 2020-05-05 | Chan Phillip P. | Director / Officer | M-Exempt | A | Common Stock | 14,100 | 9.39 | 132.4K | 714,682 | — | ↗ |
| 2020-05-05 | Capponi Vincent | Officer | M-Exempt | D | Stock Option (right to buy) | 10,123 | 3.45 | 34.9K | 0 | — | ↗ |
| 2020-05-01 | Deliargyris Efthymios | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2020-04-27 | Capponi Vincent | Officer | M-Exempt | A | Common Stock | 10,000 | 2.88 | 28.8K | 427,649 | — | ↗ |
| 2020-04-12 | Deliargyris Efthymios | Officer | A-Award | A | Common Stock | 140,000 | 0.00 | — | 140,000 | — | ↗ |
| 2020-03-10 | Capponi Vincent | Officer | S-Sale | D | Common Stock | 4,677 | 6.00 | 28.1K | 417,649 | — | ↗ |
| 2020-02-28 | Sobel Alan D. | Director | A-Award | A | Stock Option (right to buy) | 15,000 | 6.03 | 90.5K | 15,000 | — | ↗ |
| 2020-02-28 | Kraus Al | Director | A-Award | A | Stock Option (right to buy) | 30,000 | 6.03 | 180.9K | 30,000 | — | ↗ |
| 2020-02-28 | Jones Edward Raymond | Director | A-Award | A | Stock Option (right to buy) | 15,000 | 6.03 | 90.5K | 15,000 | — | ↗ |
| 2020-02-28 | Chan Phillip P. | Director / Officer | A-Award | A | Common Stock | 60,000 | 0.00 | — | 711,178 | — | ↗ |
| 2020-02-28 | Capponi Vincent | Officer | A-Award | A | Common Stock | 54,100 | 0.00 | — | 420,849 | — | ↗ |
| 2020-02-28 | BLOCH KATHLEEN P. | Officer | A-Award | A | Common Stock | 43,000 | 0.00 | — | 328,828 | — | ↗ |
| 2020-02-28 | BATOR MICHAEL G. | Director | A-Award | A | Stock Option (right to buy) | 15,000 | 6.03 | 90.5K | 15,000 | — | ↗ |
| 2019-12-10 | BLOCH KATHLEEN P. | Officer | P-Purchase | A | Common Stock | 3,000 | 3.68 | 11.0K | 291,895 | — | ↗ |
| 2019-12-06 | Chan Phillip P. | Director / Officer | P-Purchase | A | Common Stock | 16,500 | 3.60 | 59.4K | 657,688 | — | ↗ |
| 2019-11-26 | BLOCH KATHLEEN P. | Officer | P-Purchase | A | Common Stock | 1,000 | 4.27 | 4.3K | 21,000 | — | ↗ |
| 2019-08-16 | Capponi Vincent | Officer | M-Exempt | A | Common Stock | 4,600 | 4.33 | 19.9K | 372,501 | — | ↗ |
| 2019-08-16 | BLOCH KATHLEEN P. | Officer | P-Purchase | A | Common Stock | 6,500 | 4.83 | 31.4K | 20,000 | — | ↗ |
| 2019-08-15 | Chan Phillip P. | Director / Officer | M-Exempt | A | Common Stock | 75,000 | 3.45 | 258.8K | 641,188 | — | ↗ |
| 2019-08-14 | Mortensen Eric R. | Officer | M-Exempt | A | Common Stock | 5,000 | 4.50 | 22.5K | 148,932 | — | ↗ |
| 2019-08-09 | BLOCH KATHLEEN P. | Officer | P-Purchase | A | Common Stock | 1,500 | 5.52 | 8.3K | 13,500 | — | ↗ |
| 2019-07-22 | Sobel Alan D. | Director | A-Award | A | Stock Option (right to buy) | 15,000 | 7.33 | 110.0K | 15,000 | — | ↗ |
| 2019-07-22 | Mortensen Eric R. | Officer | A-Award | A | Stock Option (right to buy) | 48,700 | 7.33 | 357.0K | 48,700 | — | ↗ |
| 2019-07-22 | Kraus Al | Director | A-Award | A | Stock Option (right to buy) | 30,000 | 7.33 | 219.9K | 30,000 | — | ↗ |
| 2019-07-22 | Jones Edward Raymond | Director | A-Award | A | Stock Option (right to buy) | 15,000 | 7.33 | 110.0K | 15,000 | — | ↗ |
| 2019-07-22 | Chan Phillip P. | Director / Officer | A-Award | A | Stock Option (right to buy) | 80,000 | 7.33 | 586.4K | 80,000 | — | ↗ |
| 2019-07-22 | Capponi Vincent | Officer | A-Award | A | Stock Option (right to buy) | 68,000 | 7.33 | 498.4K | 68,000 | — | ↗ |
| 2019-07-22 | BLOCH KATHLEEN P. | Officer | A-Award | A | Stock Option (right to buy) | 60,000 | 7.33 | 439.8K | 60,000 | — | ↗ |
| 2019-07-22 | BATOR MICHAEL G. | Director | A-Award | A | Stock Option (right to buy) | 15,000 | 7.33 | 110.0K | 15,000 | — | ↗ |
| 2019-06-07 | Chan Phillip P. | Director / Officer | M-Exempt | D | Stock Option (right to buy) | 20,000 | 4.33 | 86.5K | 0 | — | ↗ |
| 2019-06-07 | BLOCH KATHLEEN P. | Officer | M-Exempt | D | Stock Option (right to buy) | 10,000 | 5.60 | 56.0K | 65,650 | — | ↗ |
| 2019-05-10 | BLOCH KATHLEEN P. | Officer | P-Purchase | A | Common Stock | 3,000 | 6.49 | 19.5K | 3,000 | — | ↗ |
| 2019-03-04 | Mortensen Eric R. | Officer | A-Award | A | Common Stock | 4,620 | 0.00 | — | 34,166 | — | ↗ |
| 2019-03-04 | Chan Phillip P. | Director / Officer | A-Award | A | Common Stock | 5,500 | 0.00 | — | 496,383 | — | ↗ |
| 2019-03-04 | Capponi Vincent | Officer | A-Award | A | Common Stock | 4,620 | 0.00 | — | 325,435 | — | ↗ |
| 2019-03-04 | BLOCH KATHLEEN P. | Officer | A-Award | A | Common Stock | 4,070 | 0.00 | — | 242,725 | — | ↗ |
| 2018-12-07 | Chan Phillip P. | Director / Officer | S-Sale | D | Common Stock | 24,337 | 9.37 | 228.0K | 503,281 | — | ↗ |
| 2018-09-07 | Chan Phillip P. | Director / Officer | S-Sale | D | Common Stock | 2,731 | 14.11 | 38.5K | 438,281 | — | ↗ |
| 2018-09-06 | Chan Phillip P. | Director / Officer | M-Exempt | A | Common Stock | 2,900 | 2.10 | 6.1K | 446,968 | — | ↗ |
| 2018-09-05 | Chan Phillip P. | Director / Officer | M-Exempt | A | Non-Statutory Stock Option (right to buy) | 600 | 2.00 | 1.2K | 0 | — | ↗ |
| 2018-08-30 | Kraus Al | Director | S-Sale | D | Common Stock | 26,000 | 14.47 | 376.3K | 125,046 | — | ↗ |
| 2018-08-29 | Capponi Vincent | Officer | M-Exempt | A | Common Stock | 20,000 | 3.45 | 69.0K | 352,768 | — | ↗ |
| 2018-08-28 | Capponi Vincent | Officer | M-Exempt | D | Stock Option (right to buy) | 9,565 | 3.45 | 33.0K | 41,300 | — | ↗ |
| 2018-08-28 | BLOCH KATHLEEN P. | Officer | M-Exempt | D | Stock Option (Right to Buy) | 10,000 | 2.88 | 28.8K | 0 | — | ↗ |
| 2018-08-14 | Jones Edward Raymond | Director | M-Exempt | D | Stock Option (right to buy) | 1,200 | 2.00 | 2.4K | 0 | — | ↗ |
| 2018-08-03 | Capponi Vincent | Officer | S-Sale | D | Common Stock | 7,600 | 13.08 | 99.4K | 332,768 | — | ↗ |
| 2018-08-03 | BLOCH KATHLEEN P. | Officer | M-Exempt | D | Stock Option (Right to Buy) | 10,000 | 2.88 | 28.8K | 10,000 | — | ↗ |
| 2018-08-02 | Capponi Vincent | Officer | S-Sale | D | Common Stock | 2,835 | 13.00 | 36.9K | 332,768 | — | ↗ |
| 2018-06-15 | Capponi Vincent | Officer | M-Exempt | D | Stock Option (Right to Buy) | 8,633 | 3.45 | 29.8K | 61,300 | — | ↗ |
| 2018-06-14 | Capponi Vincent | Officer | S-Sale | D | Common Stock | 11,367 | 12.00 | 136.4K | 356,616 | — | ↗ |
| 2018-06-11 | Chan Phillip P. | Director / Officer | X-InTheMoney | A | Common Stock | 8,000 | 3.75 | 30.0K | 461,281 | — | ↗ |
| 2018-05-31 | Jones Edward Raymond | Director | M-Exempt | D | Stock Option (right to buy) | 1,800 | 0.88 | 1.6K | 0 | — | ↗ |
| 2018-05-17 | Capponi Vincent | Officer | S-Sale | D | Common Stock | 8,000 | 10.00 | 80.0K | 337,551 | — | ↗ |
| 2018-05-16 | Capponi Vincent | Officer | M-Exempt | A | Common Stock | 4,846 | 0.88 | 4.2K | 322,397 | — | ↗ |
| 2018-05-16 | BLOCH KATHLEEN P. | Officer | M-Exempt | D | Stock Option (Right to Buy) | 12,400 | 4.69 | 58.2K | 0 | — | ↗ |
| 2018-05-15 | Capponi Vincent | Officer | M-Exempt | D | Stock Option (right to buy) | 4,000 | 4.20 | 16.8K | 8,000 | — | ↗ |
| 2018-05-15 | BLOCH KATHLEEN P. | Officer | S-Sale | D | Common Stock | 12,400 | 8.75 | 108.5K | 253,304 | — | ↗ |
| 2018-05-14 | BLOCH KATHLEEN P. | Officer | M-Exempt | D | Stock Option (Right to Buy) | 10,000 | 2.90 | 29.0K | 0 | — | ↗ |
| 2018-04-17 | BLOCH KATHLEEN P. | Officer | M-Exempt | A | Common Stock | 120 | 4.69 | 562.80 | 253,424 | — | ↗ |
| 2018-03-15 | Sobel Alan D. | Director | A-Award | A | Common Stock | 3,300 | 0.00 | — | 69,300 | — | ↗ |
| 2018-03-15 | Mortensen Eric R. | Officer | A-Award | A | Common Stock | 20,000 | 0.00 | — | 36,500 | — | ↗ |
| 2018-03-15 | Kraus Al | Director | A-Award | A | Stock Option (right to buy) | 28,875 | 7.90 | 228.1K | 28,875 | — | ↗ |
| 2018-03-15 | Jones Edward Raymond | Director | A-Award | A | Stock Option (right to buy) | 14,450 | 7.90 | 114.2K | 14,450 | — | ↗ |
| 2018-03-15 | Chan Phillip P. | Director / Officer | A-Award | A | Stock Option (right to buy) | 117,750 | 7.90 | 930.2K | 117,750 | — | ↗ |
| 2018-03-15 | Capponi Vincent | Officer | A-Award | A | Stock Option (right to buy) | 110,350 | 7.90 | 871.8K | 110,350 | — | ↗ |
| 2018-03-15 | BLOCH KATHLEEN P. | Officer | M-Exempt | D | Stock Option (Right to Buy) | 11,176 | 4.69 | 52.4K | 24,920 | — | ↗ |
| 2018-03-15 | BATOR MICHAEL G. | Director | A-Award | A | Stock Option (right to buy) | 14,450 | 7.90 | 114.2K | 14,450 | — | ↗ |
| 2018-03-13 | BLOCH KATHLEEN P. | Officer | M-Exempt | D | Stock Option (Right to Buy) | 1,104 | 4.69 | 5.2K | 36,096 | — | ↗ |
| 2018-02-28 | Mortensen Eric R. | Officer | A-Award | A | Common Stock | 14,000 | 0.00 | — | 16,500 | — | ↗ |
| 2018-02-28 | Chan Phillip P. | Director / Officer | A-Award | A | Common Stock | 43,000 | 0.00 | — | 430,413 | — | ↗ |
| 2018-02-28 | Capponi Vincent | Officer | A-Award | A | Common Stock | 38,000 | 0.00 | — | 307,451 | — | ↗ |
| 2018-02-28 | BLOCH KATHLEEN P. | Officer | A-Award | A | Common Stock | 34,700 | 0.00 | — | 250,070 | — | ↗ |
| 2018-02-21 | BLOCH KATHLEEN P. | Officer | M-Exempt | A | Common Stock | 10,000 | 2.90 | 29.0K | 268,870 | — | ↗ |
| 2018-01-16 | Capponi Vincent | Officer | M-Exempt | D | Stock Option (Right to Buy) | 44,000 | 6.25 | 275.0K | 0 | — | ↗ |
| 2018-01-12 | BLOCH KATHLEEN P. | Officer | S-Sale | D | Common Stock | 12,400 | 7.75 | 96.1K | 228,638 | — | ↗ |
| 2018-01-08 | BLOCH KATHLEEN P. | Officer | M-Exempt | D | Stock Option (Right to Buy) | 20,000 | 2.90 | 58.0K | 20,000 | — | ↗ |
| 2017-11-27 | Capponi Vincent | Officer | S-Sale | D | Common Stock | 4,000 | 7.00 | 28.0K | 271,062 | — | ↗ |
| 2017-06-09 | Mortensen Eric R. | Officer | P-Purchase | A | Common Stock | 2,500 | 4.04 | 10.1K | 2,500 | — | ↗ |
| 2017-06-09 | BATOR MICHAEL G. | Director | P-Purchase | A | Common Stock | 1,500 | 4.12 | 6.2K | 70,500 | — | ↗ |
| 2017-06-08 | Jones Edward Raymond | Director | P-Purchase | A | Common Stock | 500 | 3.98 | 2.0K | 500 | — | ↗ |
| 2017-06-08 | Chan Phillip P. | Director / Officer | P-Purchase | A | Common Stock | 3,700 | 4.00 | 14.8K | 399,907 | — | ↗ |
| 2017-06-08 | Capponi Vincent | Officer | P-Purchase | A | Common Stock | 2,500 | 4.00 | 10.0K | 275,062 | — | ↗ |
| 2017-06-06 | Mortensen Eric R. | Officer | — | D | Common Stock | 0 | 0.00 | — | 0 | — | ↗ |
| 2017-06-05 | Chan Phillip P. | Director / Officer | P-Purchase | A | Common Stock | 6,300 | 4.00 | 25.2K | 396,207 | — | ↗ |
| 2017-06-01 | Mortensen Eric R. | Officer | — | D | Stock Option (Right to Buy) | 45,000 | 4.50 | 202.5K | 0 | — | ↗ |
| 2017-05-15 | BLOCH KATHLEEN P. | Officer | P-Purchase | A | Common Stock | 1,000 | 4.34 | 4.3K | 9,000 | — | ↗ |
| 2017-02-24 | Sobel Alan D. | Director | A-Award | A | Common Stock | 6,000 | 0.00 | — | 66,000 | — | ↗ |
| 2017-02-24 | Kraus Al | Director | A-Award | A | Common Stock | 6,000 | 0.00 | — | 121,746 | — | ↗ |
| 2017-02-24 | Jones Edward Raymond | Director | A-Award | A | Stock Option (right to buy) | 13,750 | 5.60 | 77.0K | 13,750 | — | ↗ |
| 2017-02-24 | Chan Phillip P. | Director / Officer | A-Award | A | Common Stock | 40,625 | 0.00 | — | 184,207 | — | ↗ |
| 2017-02-24 | Capponi Vincent | Officer | A-Award | A | Common Stock | 35,938 | 0.00 | — | 75,662 | — | ↗ |
Executive team
Top executives
EBIT / Employee
-95.6K
Shares Outstanding
62.80M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2024 | Phillip P. Chan, MD, PhD Chief Executive Officer | 359.4K | 266.8K | 91.7K | 169.9K | — | 12.0K | 899.7K | 29.07% | ↗ |
| 2 | 2024 | Vincent J. Capponi, MS President and Chief Operating Officer | 377.5K | 169.3K | 77.4K | 227.8K | — | — | 852.0K | 35.82% | ↗ |
| 3 | 2024 | Efthymios N. Deliargyris, MD Chief Medical Officer | 363.3K | 163.0K | 58.3K | 216.4K | — | 12.5K | 813.4K | 33.76% | ↗ |
| 4 | 2024 | Peter J. Mariani Chief Financial Officer | 152.0K | 66.3K | 169.1K | 197.3K | — | — | 584.8K | 62.66% | ↗ |
| 5 | 2024 | Kathleen P. Bloch, CPA Former Chief Financial Officer | 263.0K | — | 62.1K | 91.6K | — | 19.8K | 436.4K | 35.21% | ↗ |
| 6 | 2023 | Phillip P. Chan, MD, PhD Chief Executive Officer | 482.9K | 156.9K | 307.1K | 374.5K | — | 12.0K | 1.33M | 51.12% | ↗ |
| 7 | 2023 | Vincent J. Capponi, MS President and Chief Operating Officer | 424.0K | 119.3K | 257.7K | 311.3K | — | — | 1.11M | 51.16% | ↗ |
| 8 | 2023 | Efthymios N. Deliargyris, MD Chief Medical Officer | 408.1K | 164.8K | 194.2K | 276.2K | — | 12.5K | 1.06M | 44.55% | ↗ |
| 9 | 2023 | Kathleen P. Bloch, MBA, CPA Chief Financial Officer | 258.6K | 143.4K | 89.1K | 139.1K | — | 185.8K | 816.1K | 27.96% | ↗ |
| 10 | 2023 | Kathleen P. Bloch, CPA Former Chief Financial Officer | 258.6K | 143.4K | 89.1K | 139.1K | — | 185.8K | 816.1K | 27.96% | ↗ |
| 11 | 2022 | Phillip P. Chan, MD, PhD Chief Executive Officer | 482.9K | 47.1K | 154.1K | 410.6K | — | 12.0K | 1.11M | 51.03% | ↗ |
| 12 | 2022 | Efthymios N. Deliargyris, MD Chief Medical Officer | 408.1K | 42.5K | 101.4K | 443.9K | — | 12.5K | 1.01M | 54.07% | ↗ |
| 13 | 2022 | Vincent J. Capponi, MS President and Chief Operating Officer | 424.0K | 28.6K | 134.6K | 398.8K | — | — | 985.9K | 54.09% | ↗ |
| 14 | 2022 | Kathleen P. Bloch, MBA, CPA Chief Financial Officer | 370.4K | 25.0K | 108.2K | 344.2K | — | — | 847.8K | 53.36% | ↗ |
| 15 | 2021 | Phillip P. Chan, MD, PhD Chief Executive Officer | 482.9K | 172.6K | 647.3K | 475.8K | — | 12.0K | 1.79M | 62.72% | ↗ |
| 16 | 2021 | Vincent J. Capponi, MS President and Chief Operating Officer | 424.0K | 115.3K | 559.3K | 387.6K | — | — | 1.49M | 63.71% | ↗ |
| 17 | 2021 | Kathleen P. Bloch, MBA, CPA Chief Financial Officer | 370.4K | 91.7K | 444.6K | 342.0K | — | — | 1.25M | 62.99% | ↗ |
| 18 | 2021 | Efthymios N. Deliargyris, MD Chief Medical Officer | 408.1K | 101.0K | 359.6K | 313.5K | — | 12.5K | 1.19M | 56.34% | ↗ |
| 19 | 2020 | Phillip P. Chan, MD, PhD Chief Executive Officer | 455.5K | 260.6K | 361.8K | 298.3K | — | 12.0K | 1.39M | 47.55% | ↗ |
| 20 | 2020 | Vincent J. Capponi, MS President and Chief Operating Officer | 400.0K | 198.9K | 326.2K | 253.6K | — | — | 1.18M | 49.19% | ↗ |
| 21 | 2020 | Kathleen P. Bloch, MBA, CPA Chief Financial Officer | 349.5K | 138.4K | 259.3K | 223.7K | — | — | 970.9K | 49.75% | ↗ |
| 22 | 2020 | Efthymios N. Deliargyris, MD Chief Medical Officer | 253.2K | 101.6K | 131.8K | 331.9K | — | 8.7K | 827.2K | 56.06% | ↗ |
| 23 | 2019 | Phillip P. Chan, MD, PhD President and Chief Executive Officer | 438.0K | 99.6K | 484.1K | 370.7K | — | 12.0K | 1.40M | 60.86% | ↗ |
| 24 | 2019 | Phillip P. Chan, MD, PhD Chief Executive Officer | 438.0K | 99.6K | 484.1K | 370.7K | — | 12.0K | 1.40M | 60.86% | ↗ |
| 25 | 2019 | Vincent J. Capponi, MS President and Chief Operating Officer | 363.5K | 57.3K | 433.7K | 315.1K | — | — | 1.17M | 64.02% | ↗ |
| 26 | 2019 | Vincent J. Capponi, MS Chief Operating Officer | 363.5K | 57.3K | 433.7K | 315.1K | — | — | 1.17M | 64.02% | ↗ |
| 27 | 2019 | Kathleen P. Bloch, MBA, CPA Chief Financial Officer | 323.0K | 50.9K | 348.0K | 278.0K | — | — | 999.8K | 62.60% | ↗ |
| 28 | 2018 | Phillip P. Chan, MD, PhD President and Chief Executive Officer | 400.0K | 160.0K | 337.6K | 337.7K | — | 12.0K | 1.25M | 54.14% | ↗ |
| 29 | 2018 | Phillip P. Chan, MD, PhD Chief Executive Officer | 400.0K | 160.0K | 337.6K | 337.7K | — | 12.0K | 1.25M | 54.14% | ↗ |
| 30 | 2018 | Vincent J. Capponi, MS President and Chief Operating Officer | 332.0K | 132.8K | 298.3K | 316.5K | — | — | 1.08M | 56.95% | ↗ |
| 31 | 2018 | Vincent J. Capponi, MS Chief Operating Officer | 332.0K | 132.8K | 298.3K | 316.5K | — | — | 1.08M | 56.95% | ↗ |
| 32 | 2018 | Kathleen P. Bloch, MBA, CPA Chief Financial Officer | 295.0K | 118.0K | 272.4K | 268.2K | — | — | 953.6K | 56.69% | ↗ |
| 33 | 2018 | Eric R. Mortensen, MD, PhDChief Medical Officer | 339.0K | 101.7K | 109.9K | 229.5K | — | — | 780.1K | 43.50% | ↗ |
| 34 | 2017 | Phillip P. Chan, MD, PhD President and Chief Executive Officer | 378.0K | — | 227.5K | 210.1K | — | 12.0K | 827.6K | 52.88% | ↗ |
| 35 | 2017 | Vincent J. Capponi, MS Chief Operating Officer | 314.0K | — | 201.3K | 198.2K | — | — | 713.4K | 55.99% | ↗ |
| 36 | 2017 | Kathleen P. Bloch, MBA, CPA Chief Financial Officer | 275.0K | — | 183.8K | 167.9K | — | — | 626.6K | 56.11% | ↗ |
| 37 | 2017 | Eric R. Mortensen, MD, PhDChief Medical Officer | 186.6K | — | — | 116.7K | — | — | 303.3K | 38.48% | ↗ |
| 38 | 2017 | Eric R. Mortensen, MD, PhD Chief Medical Officer | 186.6K | — | — | 116.7K | — | — | 303.3K | 38.48% | ↗ |
| 39 | 2017 | Robert H. Bartlett, MD Chief Medical Officer | — | — | — | 43.3K | — | 54.0K | 97.3K | 44.51% | ↗ |
| 40 | 2016 | Phillip P. Chan, MD, PhD President and Chief Executive Officer | 350.0K | — | 121.9K | 23.3K | — | 12.0K | 507.2K | 28.63% | ↗ |
| 41 | 2016 | Vincent J. Capponi, MS Chief Operating Officer | 291.0K | — | 107.9K | 21.9K | — | — | 420.8K | 30.85% | ↗ |
| 42 | 2016 | Kathleen P. Bloch, MBA, CPA Chief Financial Officer | 255.0K | — | 98.5K | 18.6K | — | — | 372.1K | 31.47% | ↗ |
| 43 | 2016 | Robert H. Bartlett, MD Chief Medical Officer | — | — | — | 6.6K | — | 54.0K | 60.6K | 10.96% | ↗ |
| 44 | 2015 | Phillip P. Chan, MD, PhD President and Chief Executive Officer | 325.0K | — | — | 96.0K | — | — | 421.0K | 22.80% | ↗ |
| 45 | 2015 | Vincent J. Capponi, MS Chief Operating Officer | 270.0K | — | — | 90.5K | — | — | 360.5K | 25.10% | ↗ |
| 46 | 2015 | Kathleen P. Bloch, MBA, CPA Chief Financial Officer | 235.0K | — | — | 76.8K | — | — | 311.8K | 24.62% | ↗ |
| 47 | 2015 | Kathleen P. Bloch, CPA Chief Financial Officer | 235.0K | — | — | — | — | — | 235.0K | 0.00% | ↗ |
| 48 | 2015 | Robert H. Bartlett, MD Chief Medical Officer | — | 10.0K | — | 27.4K | — | 54.0K | 91.4K | 29.99% | ↗ |
| 49 | 2014 | Phillip P. Chan, MD, PhD President and Chief Executive Officer | 245.4K | 50.0K | — | 22.9K | — | — | 318.3K | 7.19% | ↗ |
| 50 | 2014 | Phillip Chan Chief Executive Officer | 245.4K | 50.0K | — | 22.9K | — | — | 318.3K | 7.19% | ↗ |
| 51 | 2014 | Vincent Capponi, Chief Operating Officer | 239.4K | 40.0K | — | 22.5K | — | — | 301.9K | 7.45% | ↗ |
| 52 | 2014 | Vincent J. Capponi, MS Chief Operating Officer | 239.4K | 40.0K | — | 22.5K | — | — | 301.9K | 7.45% | ↗ |
| 53 | 2014 | Kathleen P. Bloch, CPA Chief Financial Officer | 200.0K | 55.0K | — | 15.0K | — | — | 270.0K | 5.56% | ↗ |
| 54 | 2014 | Kathleen P. Bloch, MBA, CPA Chief Financial Officer | 200.0K | 55.0K | — | 15.0K | — | — | 270.0K | 5.56% | ↗ |
| 55 | 2014 | Kathleen P. Bloch, Chief Financial Officer | 200.0K | 55.0K | — | 15.0K | — | — | 270.0K | 5.56% | ↗ |
| 56 | 2014 | Ronald Berger Interim Chief Financial Officer | — | — | — | 5.6K | — | 94.4K | 100.0K | 5.55% | ↗ |
| 57 | 2014 | Dr. Robert Bartlett Chief Medical Officer | — | — | — | 6.0K | — | 53.0K | 59.0K | 10.17% | ↗ |
| 58 | 2014 | Robert H. Bartlett, MD Chief Medical Officer | — | — | — | 6.0K | — | 53.0K | 59.0K | 10.17% | ↗ |
| 59 | 2013 | Phillip P. Chan, MD, PhD President and Chief Executive Officer | 245.4K | — | — | — | — | — | 245.4K | 0.00% | ↗ |
| 60 | 2013 | Phillip Chan Chief Executive Officer | 245.4K | — | — | — | — | — | 245.4K | 0.00% | ↗ |
| 61 | 2013 | Vincent Capponi, Chief Operating Officer | 239.4K | 200.00 | — | — | — | — | 239.6K | 0.00% | ↗ |
| 62 | 2013 | Vincent Capponi Chief Operating Officer | 222.4K | 200.00 | — | — | — | — | 239.6K | 0.00% | ↗ |
| 63 | 2013 | Vincent J. Capponi, MS Chief Operating Officer | 239.4K | 200.00 | — | — | — | — | 239.6K | 0.00% | ↗ |
| 64 | 2013 | Kathleen P. Bloch, CPA Chief Financial Officer | 119.0K | — | — | 5.4K | — | — | 124.5K | 4.32% | ↗ |
| 65 | 2013 | Kathleen P. Bloch, Chief Financial Officer | 119.0K | — | — | — | — | — | 124.5K | 0.00% | ↗ |
| 66 | 2013 | Kathleen P. Bloch Chief Financial Officer | 119.0K | — | — | 5.4K | — | — | 124.5K | 4.32% | ↗ |
| 67 | 2013 | Ronald Berger Interim Chief Financial Officer | — | 200.00 | — | — | — | 100.5K | 110.5K | 0.00% | ↗ |
| 68 | 2013 | Robert H. Bartlett, MD Chief Medical Officer | — | — | — | — | — | 52.0K | 52.0K | 0.00% | ↗ |
| 69 | 2013 | Dr. Robert Bartlett Chief Medical Officer | — | — | — | — | — | 52.0K | 52.0K | 0.00% | ↗ |
| 70 | 2013 | David Lamadrid Chief Financial Officer | — | — | — | — | — | — | — | — | ↗ |
| 71 | 2012 | Vincent Capponi Chief Operating Officer | 219.7K | 30.2K | — | — | — | — | 249.9K | 0.00% | ↗ |
| 72 | 2012 | Phillip Chan Chief Executive Officer | 231.5K | — | — | — | — | 8.0K | 239.5K | 0.00% | ↗ |
| 73 | 2012 | David Lamadrid Chief Financial Officer | 108.7K | — | — | — | — | — | 108.7K | 0.00% | ↗ |
| 74 | 2012 | Ronald Berger Interim Chief Financial Officer | — | 200.00 | — | 1.0K | — | 102.5K | 103.7K | 0.99% | ↗ |
| 75 | 2012 | Dr. Robert Bartlett Chief Medical Officer | — | — | — | — | — | 52.0K | 52.0K | 0.00% | ↗ |
| 76 | 2012 | Kathleen P. Bloch Chief Financial Officer | — | — | — | — | — | — | — | — | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Phillip Chan | Chief Executive Officer & Director | 602.0K | — |
| Vincent J. Capponi | President & Chief Operating Officer | 543.1K | male |
| Efthymios N. Deliargyris FACC FESC FSCAI | Chief Medical Officer | 523.2K | — |
| Peter J. Mariani | Chief Financial Officer | 521.8K | male |
| Kathleen Bloch | Advisor | 282.8K | female |
| Robert H. Bartlett | Co-Chairman of Cardiac Surgery Advisory Board & Consultant | 54.0K | — |
| Christian Steiner | Executive Vice President of Sales & Marketing | — | — |
| Jodi Hoover | Executive | — | — |
| Christopher Cramer | Senior Vice President of Business Development | — | male |
ESG Rating
ESG Score History MEDICAL - DEVICES
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for CTSO
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
